<DOC>
	<DOCNO>NCT00911963</DOCNO>
	<brief_summary>The purpose study assess antiviral activity administer alone 3 day combination peginterferon ribavirin 12 week . This study also evaluate safety tolerability treatment VCH-222 give alone combination peginterferon ribavirin . The study also evaluate pharmacokinetic profile VCH-222 HCV infected subject .</brief_summary>
	<brief_title>Pharmacokinetics Multiple Ascending Doses VCH-222 Subjects With Chronic Hepatitis C Infection</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>Male Female subject , 1865 year age ( female nonchild bear potential Part B ) Have laboratory evidence HCV infection 6 month , define ( 1 ) presence antiHCV antibody ( Genotype 1a 1b infection ) , ( 2 ) document HCV RNA presence sensitive specific assay ( 3 histologic evidence CHC ( Fibrosis standardize histological grading system ) Plasma HCV RNA 100,000 IU/ml HIV 1 HIV2 ab seronegative Body Mass Index ( BMI ) â‰¤ 35 kg/m2 BMI Treatment Naive subject Contraindications peginterferon ribavirin therapy Have evidence liver cirrhosis , decompensated liver disease , ChildPugh score &gt; 5 Have hemoglobinopathy , unstable cardiac disease , history organ transplant , active malignant disease uncontrolled Type I II diabetes</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>VX-222</keyword>
</DOC>